CellWell record HH-149643
PD-1 inhibitors combined with tyrosine kinase inhibitor-associated hypothyroidism is a predictive factor for antitumor effectiveness in male patients with hepatocellular carcinoma
Bailu Cao; Min Ai; Ping Huang; Huan Zhong
2026
In plain language
In male hepatocellular carcinoma patients, PD-1 inhibitor plus tyrosine kinase inhibitor-induced hypothyroidism was associated with significantly prolonged progression-free survival.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-149643
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.